Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer

Frédéric D. Birkhäuser, Urs E. Studer, Johannes M. Froehlich, Maria Triantafyllou, Lauren J. Bains, Giuseppe Petralia, Peter Vermathen, Achim Fleischmann, Harriet C. Thoeny

Research output: Contribution to journalArticle

Abstract

Background Conventional cross-sectional imaging with computed tomography and magnetic resonance imaging (MRI) has limited accuracy for lymph node (LN) staging in bladder and prostate cancer patients. Objective To prospectively assess the diagnostic accuracy of combined ultrasmall superparamagnetic particles of iron oxide (USPIO) MRI and diffusion-weighted (DW) MRI in staging of normal-sized pelvic LNs in bladder and/or prostate cancer patients. Design, setting, and participants Examinations with 3-Tesla MRI 24-36 h after administration of USPIO using conventional MRI sequences combined with DW-MRI (USPIO-DW-MRI) were performed in 75 patients with clinically localised bladder and/or prostate cancer staged previously as N0 by conventional cross-sectional imaging. Combined USPIO-DW-MRI findings were analysed by three independent readers and correlated with histopathologic LN findings after extended pelvic LN dissection (PLND) and resection of primary tumours. Outcome measurements and statistical analysis Sensitivity and specificity for LN status of combined USPIO-DW-MRI versus histopathologic findings were evaluated per patient (primary end point) and per pelvic side (secondary end point). Time required for combined USPIO-DW-MRI reading was assessed. Results and limitations At histopathologic analysis, 2993 LNs (median: 39 LNs; range: 17-68 LNs per patient) with 54 LN metastases (1.8%) were found in 20 of 75 (27%) patients. Per-patient sensitivity and specificity for detection of LN metastases by the three readers ranged from 65% to 75% and 93% to 96%, respectively; sensitivity and specificity per pelvic side ranged from 58% to 67% and 94% to 97%, respectively. Median reading time for the combined USPIO-DW-MRI images was 9 min (range: 3-26 min). A potential limitation is the absence of a node-to-node correlation of combined USPIO-DW-MRI and histopathologic analysis. Conclusions Combined USPIO-DW-MRI improves detection of metastases in normal-sized pelvic LNs of bladder and/or prostate cancer patients in a short reading time. This trial is registered with ClinicalTrials.gov (identifier NCT00622973).

Original languageEnglish
Pages (from-to)953-960
Number of pages8
JournalEuropean Urology
Volume64
Issue number6
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Diffusion Magnetic Resonance Imaging
Urinary Bladder Neoplasms
Prostatic Neoplasms
Lymph Nodes
Neoplasm Metastasis
Magnetic Resonance Imaging
Reading
Sensitivity and Specificity
ferumoxtran-10
Lymph Node Excision
Tomography

Keywords

  • Bladder cancer
  • Diffusion-weighted MRI
  • Lymph node metastasis
  • Pelvic lymph node dissection
  • Prostate cancer
  • USPIO

ASJC Scopus subject areas

  • Urology

Cite this

Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. / Birkhäuser, Frédéric D.; Studer, Urs E.; Froehlich, Johannes M.; Triantafyllou, Maria; Bains, Lauren J.; Petralia, Giuseppe; Vermathen, Peter; Fleischmann, Achim; Thoeny, Harriet C.

In: European Urology, Vol. 64, No. 6, 12.2013, p. 953-960.

Research output: Contribution to journalArticle

Birkhäuser, Frédéric D. ; Studer, Urs E. ; Froehlich, Johannes M. ; Triantafyllou, Maria ; Bains, Lauren J. ; Petralia, Giuseppe ; Vermathen, Peter ; Fleischmann, Achim ; Thoeny, Harriet C. / Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. In: European Urology. 2013 ; Vol. 64, No. 6. pp. 953-960.
@article{d64e0fd6778c4e16b6a08e757bfbfec7,
title = "Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer",
abstract = "Background Conventional cross-sectional imaging with computed tomography and magnetic resonance imaging (MRI) has limited accuracy for lymph node (LN) staging in bladder and prostate cancer patients. Objective To prospectively assess the diagnostic accuracy of combined ultrasmall superparamagnetic particles of iron oxide (USPIO) MRI and diffusion-weighted (DW) MRI in staging of normal-sized pelvic LNs in bladder and/or prostate cancer patients. Design, setting, and participants Examinations with 3-Tesla MRI 24-36 h after administration of USPIO using conventional MRI sequences combined with DW-MRI (USPIO-DW-MRI) were performed in 75 patients with clinically localised bladder and/or prostate cancer staged previously as N0 by conventional cross-sectional imaging. Combined USPIO-DW-MRI findings were analysed by three independent readers and correlated with histopathologic LN findings after extended pelvic LN dissection (PLND) and resection of primary tumours. Outcome measurements and statistical analysis Sensitivity and specificity for LN status of combined USPIO-DW-MRI versus histopathologic findings were evaluated per patient (primary end point) and per pelvic side (secondary end point). Time required for combined USPIO-DW-MRI reading was assessed. Results and limitations At histopathologic analysis, 2993 LNs (median: 39 LNs; range: 17-68 LNs per patient) with 54 LN metastases (1.8{\%}) were found in 20 of 75 (27{\%}) patients. Per-patient sensitivity and specificity for detection of LN metastases by the three readers ranged from 65{\%} to 75{\%} and 93{\%} to 96{\%}, respectively; sensitivity and specificity per pelvic side ranged from 58{\%} to 67{\%} and 94{\%} to 97{\%}, respectively. Median reading time for the combined USPIO-DW-MRI images was 9 min (range: 3-26 min). A potential limitation is the absence of a node-to-node correlation of combined USPIO-DW-MRI and histopathologic analysis. Conclusions Combined USPIO-DW-MRI improves detection of metastases in normal-sized pelvic LNs of bladder and/or prostate cancer patients in a short reading time. This trial is registered with ClinicalTrials.gov (identifier NCT00622973).",
keywords = "Bladder cancer, Diffusion-weighted MRI, Lymph node metastasis, Pelvic lymph node dissection, Prostate cancer, USPIO",
author = "Birkh{\"a}user, {Fr{\'e}d{\'e}ric D.} and Studer, {Urs E.} and Froehlich, {Johannes M.} and Maria Triantafyllou and Bains, {Lauren J.} and Giuseppe Petralia and Peter Vermathen and Achim Fleischmann and Thoeny, {Harriet C.}",
year = "2013",
month = "12",
doi = "10.1016/j.eururo.2013.07.032",
language = "English",
volume = "64",
pages = "953--960",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "6",

}

TY - JOUR

T1 - Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer

AU - Birkhäuser, Frédéric D.

AU - Studer, Urs E.

AU - Froehlich, Johannes M.

AU - Triantafyllou, Maria

AU - Bains, Lauren J.

AU - Petralia, Giuseppe

AU - Vermathen, Peter

AU - Fleischmann, Achim

AU - Thoeny, Harriet C.

PY - 2013/12

Y1 - 2013/12

N2 - Background Conventional cross-sectional imaging with computed tomography and magnetic resonance imaging (MRI) has limited accuracy for lymph node (LN) staging in bladder and prostate cancer patients. Objective To prospectively assess the diagnostic accuracy of combined ultrasmall superparamagnetic particles of iron oxide (USPIO) MRI and diffusion-weighted (DW) MRI in staging of normal-sized pelvic LNs in bladder and/or prostate cancer patients. Design, setting, and participants Examinations with 3-Tesla MRI 24-36 h after administration of USPIO using conventional MRI sequences combined with DW-MRI (USPIO-DW-MRI) were performed in 75 patients with clinically localised bladder and/or prostate cancer staged previously as N0 by conventional cross-sectional imaging. Combined USPIO-DW-MRI findings were analysed by three independent readers and correlated with histopathologic LN findings after extended pelvic LN dissection (PLND) and resection of primary tumours. Outcome measurements and statistical analysis Sensitivity and specificity for LN status of combined USPIO-DW-MRI versus histopathologic findings were evaluated per patient (primary end point) and per pelvic side (secondary end point). Time required for combined USPIO-DW-MRI reading was assessed. Results and limitations At histopathologic analysis, 2993 LNs (median: 39 LNs; range: 17-68 LNs per patient) with 54 LN metastases (1.8%) were found in 20 of 75 (27%) patients. Per-patient sensitivity and specificity for detection of LN metastases by the three readers ranged from 65% to 75% and 93% to 96%, respectively; sensitivity and specificity per pelvic side ranged from 58% to 67% and 94% to 97%, respectively. Median reading time for the combined USPIO-DW-MRI images was 9 min (range: 3-26 min). A potential limitation is the absence of a node-to-node correlation of combined USPIO-DW-MRI and histopathologic analysis. Conclusions Combined USPIO-DW-MRI improves detection of metastases in normal-sized pelvic LNs of bladder and/or prostate cancer patients in a short reading time. This trial is registered with ClinicalTrials.gov (identifier NCT00622973).

AB - Background Conventional cross-sectional imaging with computed tomography and magnetic resonance imaging (MRI) has limited accuracy for lymph node (LN) staging in bladder and prostate cancer patients. Objective To prospectively assess the diagnostic accuracy of combined ultrasmall superparamagnetic particles of iron oxide (USPIO) MRI and diffusion-weighted (DW) MRI in staging of normal-sized pelvic LNs in bladder and/or prostate cancer patients. Design, setting, and participants Examinations with 3-Tesla MRI 24-36 h after administration of USPIO using conventional MRI sequences combined with DW-MRI (USPIO-DW-MRI) were performed in 75 patients with clinically localised bladder and/or prostate cancer staged previously as N0 by conventional cross-sectional imaging. Combined USPIO-DW-MRI findings were analysed by three independent readers and correlated with histopathologic LN findings after extended pelvic LN dissection (PLND) and resection of primary tumours. Outcome measurements and statistical analysis Sensitivity and specificity for LN status of combined USPIO-DW-MRI versus histopathologic findings were evaluated per patient (primary end point) and per pelvic side (secondary end point). Time required for combined USPIO-DW-MRI reading was assessed. Results and limitations At histopathologic analysis, 2993 LNs (median: 39 LNs; range: 17-68 LNs per patient) with 54 LN metastases (1.8%) were found in 20 of 75 (27%) patients. Per-patient sensitivity and specificity for detection of LN metastases by the three readers ranged from 65% to 75% and 93% to 96%, respectively; sensitivity and specificity per pelvic side ranged from 58% to 67% and 94% to 97%, respectively. Median reading time for the combined USPIO-DW-MRI images was 9 min (range: 3-26 min). A potential limitation is the absence of a node-to-node correlation of combined USPIO-DW-MRI and histopathologic analysis. Conclusions Combined USPIO-DW-MRI improves detection of metastases in normal-sized pelvic LNs of bladder and/or prostate cancer patients in a short reading time. This trial is registered with ClinicalTrials.gov (identifier NCT00622973).

KW - Bladder cancer

KW - Diffusion-weighted MRI

KW - Lymph node metastasis

KW - Pelvic lymph node dissection

KW - Prostate cancer

KW - USPIO

UR - http://www.scopus.com/inward/record.url?scp=84887406161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887406161&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2013.07.032

DO - 10.1016/j.eururo.2013.07.032

M3 - Article

C2 - 23916692

AN - SCOPUS:84887406161

VL - 64

SP - 953

EP - 960

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -